NCT02571192View on ClinicalTrials.gov

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

October 1, 2015

Study Completion Date

October 1, 2015

Conditions
Non-Alcoholic Steatohepatitis
Interventions
DRUG

SHP626

single oral dose 50mg SHP626 with approximately 5.95 μCi RAD

RADIATION

5.95 μCi RAD

Trial Locations (1)

53704

Covance Madison Clinical Research Unit, Madison

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY